$-1.92
(Market cap
$0 Mln
Revenue (TTM)
$-- Mln
P/E Ratio
--
P/B Ratio
1.3
Div. Yield
0 %
Stock Range
Today’s Range
52 Week Range
Liquidity
Fundamentals
-
Net Profit (TTM)
$-- Mln
-
ROE
-7.3 %
-
ROCE
-- %
-
Industry P/E
--
-
EV/EBITDA
-5
-
Debt to Equity
--
-
Book Value
$--
-
EPS
$-9.3
-
Face value
--
-
Shares outstanding
9,799,538
10 Years Aggregate
CFO
$-198.25 Mln
EBITDA
$-232.15 Mln
Net Profit
$-259.32 Mln
Performance
|
Company
|
YTD
|
1 Month
|
3 Months
|
1 Year
|
3 Years
|
5 Years
|
10 Years
|
|---|---|---|---|---|---|---|---|
|
Orgenesis (ORGS)
| -- | -- | -- | -- | -82.2 | -77.0 | -52.1 |
|
BSE Sensex*
| -10.7 | -3.6 | 1.9 | -6.3 | 4.5 | 5.4 | 10.1 |
|
S&P Small-Cap 600#
| -5.8 | -5.3 | -13.7 | -6.3 | 5.3 | 3.0 | 5.5 |
|
Company
|
2023
|
2022
|
2021
|
2020
|
2019
|
2018
|
2017
|
|---|---|---|---|---|---|---|---|
|
Orgenesis (ORGS)
| -74.4 | -32.3 | -36.0 | -3.4 | -0.4 | -18.6 | 54.7 |
|
S&P Small-Cap 600
| 13.9 | -17.4 | 25.3 | 9.6 | 20.9 | -9.7 | 11.7 |
|
BSE Sensex
| 18.7 | 4.4 | 22.0 | 15.8 | 14.4 | 5.9 | 27.9 |
Essential Checks
View DetailsIs there a threat to the company's solvency?
Can creative accounting be detected through the financial numbers?
How did the company perform in the last one year?
Financials
View DetailsKey Ratios
View Details
5Y Avg -- 3Y Avg -- TTM --
P/E Ratio
--
--Min --Median --Max
P/B Ratio
--
--Min --Median --Max
Earnings Yield (%)
--
Earnings Yield (%) = EBIT / Enterprise value
PEG Ratio
--
Price = Price / Earnings to growth ratio
Peers
View DetailsCompany |
Price ($) | Market Cap ($ Mln) | Revenue (TTM) | Net Profit (TTM) | OPM (%) | ROE (%) | P/E | P/B |
|---|---|---|---|---|---|---|---|---|
|
Orgenesis (ORGS)
|
0.0 | 0.3 | 1.0 | -48.2 | -- | 164.7 | -- | 1.3 |
| 62.7 | 8,162.7 | 616.9 | -75.1 | 1.7 | -9.3 | -- | 10.0 | |
| 15.0 | 10,125.1 | 6,561.1 | -578.0 | -4.5 | -10.3 | -- | 1.8 | |
| 365.1 | 9,761.6 | 2,589.3 | 222.4 | -6.0 | 3 | 44.5 | 1.4 | |
| 58.5 | 8,913.0 | 3,499.6 | -71.2 | 0.5 | -3.2 | -- | 3.8 | |
| 177.5 | 10,637.8 | 612.8 | -188.1 | -30.6 | -28.1 | -- | 15.3 | |
| 101.0 | 6,590.6 | 1,556.3 | 275.3 | 24.6 | 22.9 | 24.2 | 5.0 | |
| 322.2 | 12,649.5 | 1,504.9 | 160.6 | 13.6 | 10.9 | 79.3 | 8.3 | |
| 167.6 | 9,458.6 | 785.1 | 41.5 | 9.9 | 2 | 232.8 | 4.6 | |
| 28.9 | 12,007.0 | 6,164.0 | 625.0 | 13.0 | 11.8 | 19.5 | 2.3 |
Shareholding Pattern
View DetailsAbout Orgenesis (ORGS)
Orgenesis Inc., a biotech company, focuses on cell and gene therapies in the United States. It operates through two segments: Octomera and Therapies. The company develops a Point of Care (POCare) platform that includes a pipeline of licensed cell... based POCare therapies that are processed and produced under closed and automated POCare technology systems across a collaborative POCare model, POCare network consisting of research institutes and hospitals. Its therapies include autologous; cell-based immunotherapies; and therapeutics for metabolic diseases, anti-viral diseases, and tissue regeneration. It also provides hospital services and cell process development services. The company was formerly known as Business Outsourcing Service, Inc. and changed its name to Orgenesis Inc. in August 2011. Orgenesis Inc. was incorporated in 2008 and is headquartered in Germantown, Maryland. Read more
-
Chairperson of the Board, CEO & President
Ms. Vered Caplan M.Sc.
-
Chairperson of the Board, CEO & President
Ms. Vered Caplan M.Sc.
-
Headquarters
Germantown, MD
-
Website
Value Research Ratings
Our rating system has guided millions of investors in the past 20 years.
FAQs for Orgenesis (ORGS)
What is the current share price of Orgenesis Inc (ORGS) Today?
The share price of Orgenesis Inc (ORGS) is $0.03 (NASDAQ) as of 04-Sep-2026 09:30 EDT. Orgenesis Inc (ORGS) has given a return of -82.2% in the last 3 years.
What is the current PB & PE ratio of Orgenesis Inc (ORGS)?
Since, TTM earnings of Orgenesis Inc (ORGS) is negative, P/E ratio is not available.
PE & PB ratio at the end of financial year.
| Year | P/E Ratio | P/B Ratio |
|---|---|---|
2024 |
-- |
-- |
2023 |
-0.29 |
-0.75 |
2023 |
-- |
-- |
2022 |
-3.35 |
1.81 |
2022 |
-- |
-- |
What is the 52 Week High and Low of Orgenesis Inc (ORGS)?
The 52-week high and low of Orgenesis Inc (ORGS) are Rs 0.03 and Rs 0.03 as of 08-Sep-2026.
What is the market cap of Orgenesis Inc (ORGS)?
Orgenesis Inc (ORGS) has a market capitalisation of $ 0 Mln as on 04-Sep-2026. As per SEBI classification, it is a Small Cap company.
Should I invest in Orgenesis Inc (ORGS)?
Before investing in Orgenesis Inc (ORGS), assess your goals, risk tolerance, and if the company aligns with your long-term plan. Carefully review its business model, financials, and valuation. Avoid making decisions based on tips or short-term trends.
New Process Alert 
Seems like you've uploaded a wrong QR code. Please upload the QR code downloaded from MF Central platform.